Introduction: The Dual Nature of a Trace Mineral

Selenium is a trace mineral essential for human health, yet its relationship with diabetes risk remains one of the most debated topics in nutritional science. While selenium’s role in antioxidant defense and thyroid hormone metabolism is well established, research over the past two decades has produced conflicting evidence regarding its effect on glucose homeostasis and type 2 diabetes. For healthcare professionals and researchers, understanding this nuanced connection is critical—especially as selenium supplementation gains popularity among individuals seeking to boost immunity or prevent chronic disease. This article synthesizes current evidence on selenium’s biochemistry, epidemiological findings, mechanistic pathways, and clinical implications to provide a balanced view of how selenium may influence diabetes risk.

The Biochemistry of Selenium in Human Physiology

Selenium exerts its biological functions primarily through selenoproteins—proteins that incorporate selenium as the amino acid selenocysteine. Over 25 selenoproteins have been identified in humans, including glutathione peroxidases (GPx), thioredoxin reductases (TXNRD), and iodothyronine deiodinases (DIO). These enzymes are central to redox regulation, antioxidant defense, thyroid hormone activation, and immune function. The body’s selenium status is tightly controlled by intake, absorption, and renal excretion, with the liver acting as a primary storage site.

Dietary selenium exists in two main forms: inorganic (selenite, selenate) and organic (selenomethionine, selenocysteine). Organic selenium is more bioavailable and can be nonspecifically incorporated into proteins in place of methionine, creating a reservoir that buffers against short-term deficiency. The Institute of Medicine’s Recommended Dietary Allowance (RDA) for selenium is 55 μg/day for adults, with an upper tolerable intake level (UL) set at 400 μg/day to prevent selenosis.

Biomarkers of Selenium Status

Common biomarkers include serum selenium, plasma selenoprotein P (SELENOP), and erythrocyte GPx activity. Serum selenium reflects recent intake, while SELENOP indicates long-term status and delivery to tissues. These markers are used in epidemiological studies but vary by geographic region due to differences in soil selenium content. For instance, populations in the United States typically have higher selenium levels than those in parts of Europe, China, or New Zealand.

Epidemiological Evidence: Mixed Signals

The association between selenium and diabetes risk has been examined in numerous cross-sectional and prospective cohort studies, yielding divergent results. Some of the most influential data come from the National Health and Nutrition Examination Survey (NHANES) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Studies Suggesting Increased Risk

A seminal analysis of NHANES III (1988–1994) found that participants in the highest quartile of serum selenium had a significantly higher prevalence of type 2 diabetes compared with those in the lowest quartile. After adjusting for confounders, the odds ratio for diabetes was 1.97 for the highest versus lowest quartile. Subsequent prospective analyses within the same cohort confirmed a dose-response relationship, with each 10 μg/dL increase in serum selenium associated with a 14% higher risk of incident diabetes.

Similarly, the SELECT trial, which originally investigated the role of selenium and vitamin E in prostate cancer prevention, reported a concerning trend: men assigned to selenium (200 μg/day as L-selenomethionine) had a modest but nonsignificant increase in type 2 diabetes incidence (hazard ratio 1.07; 95% CI, 0.94–1.22). Post-hoc analyses suggested the risk was more pronounced in individuals with higher baseline selenium levels.

Studies Suggesting Protective or Null Effects

Other observational studies have reported inverse associations. For example, the French SU.VI.MAX trial found that after 7.5 years, participants with higher baseline selenium concentrations had lower fasting glucose and lower incidence of metabolic syndrome. However, these effects were observed in a population with relatively low selenium status. A meta-analysis of 16 prospective studies published in Nutrition & Diabetes concluded that while high selenium exposure increased diabetes risk in individuals with adequate or high baseline status, low selenium levels were associated with impaired glucose tolerance and higher HbA1c in selenium-deficient populations.

Important caveat: many observational studies are confounded by lifestyle factors, dietary patterns, and comorbidities. Selenium intake is often correlated with consumption of nuts, fish, and red meat, which themselves influence diabetes risk. Thus, causality cannot be inferred from these associations alone.

Mechanisms Linking Selenium to Glucose Metabolism

Understanding the biological plausibility behind the selenium–diabetes connection requires examining several pathways: oxidative stress and insulin signaling, selenoprotein expression, and thyroid hormone regulation.

Oxidative Stress and Insulin Resistance

Insulin resistance is characterized by impaired insulin signaling, often accompanied by elevated reactive oxygen species (ROS). At low to moderate levels, ROS act as second messengers in insulin signaling, but excessive oxidative stress disrupts the cascade. Selenium, through glutathione peroxidases and thioredoxin reductases, helps neutralize ROS. However, overactivation of these antioxidant enzymes may paradoxically suppress ROS-mediated signaling that is essential for normal insulin action.

In vitro studies show that supraphysiological selenium concentrations increase the expression of GPx1, which consumes intracellular hydrogen peroxide. This reduction in H₂O₂ blunts the activation of stress-sensitive kinases like JNK and IKKβ, but also attenuates the redox-sensitive steps of the insulin signaling cascade, including IRS-1 tyrosine phosphorylation and Akt activation. The resulting impairment mimics chronic insulin resistance in cell culture models.

Selenoprotein P and Insulin Resistance

Selenoprotein P (SELENOP) is the major selenium transport protein, but it also has enzymatic activity as a phospholipid hydroperoxide glutathione peroxidase. Elevated SELENOP levels have been linked to insulin resistance in both human and animal studies. In the liver, SELENOP expression is regulated by glucose and insulin via the transcription factor FoxO1. Excess SELENOP can inhibit insulin signaling in hepatocytes and skeletal muscle by binding to the low-density lipoprotein receptor-related protein 8 (LRP8) and activating AMPK-independent pathways. Mice lacking SELENOP show improved glucose tolerance, further supporting a role for this selenoprotein in the pathogenesis of type 2 diabetes.

Thyroid Hormone Interaction

Selenium is critical for the synthesis of the iodothyronine deiodinases (DIO1, DIO2, DIO3), which convert thyroxine (T4) to the active triiodothyronine (T3). Thyroid hormones influence glucose metabolism by modulating insulin sensitivity and gluconeogenesis. Both selenium deficiency and excess can disrupt thyroid function, potentially altering diabetes risk. For instance, in regions with combined iodine and selenium deficiency, hypothyroidism and subsequent metabolic disturbances are common. Conversely, excessive selenium intake may suppress DIO activity and reduce T3 levels, leading to a hypothyroid-like state that promotes weight gain and insulin resistance.

The U-Shaped Relationship: A Unifying Hypothesis

Given the contradictory evidence, many researchers propose a U-shaped dose-response curve for selenium and diabetes risk. Both too little and too much selenium are harmful, while a narrow optimal range supports normal glucose metabolism. This concept is supported by animal models: selenium deficiency impairs glucose tolerance, while supranutritional supplementation induces insulin resistance.

In humans, the “safe” window appears to correspond to serum selenium levels between 90 and 130 μg/L. Below 70 μg/L, signs of deficiency (cardiomyopathy, myopathy, impaired immune function) increase, along with potential worsening of glycemic control. Above 140–150 μg/L, insulin resistance biomarkers rise. The threshold varies by individual based on genetic polymorphisms, selenium form, and coexisting nutrient deficiencies.

Genetic Variability and Personalization

Polymorphisms in selenoprotein genes influence how individuals respond to selenium intake. For example, the rs3877899 variant in the SEPP1 gene (encoding SELENOP) affects selenium metabolism and diabetes risk. Carriers of the A allele may have lower plasma selenium but higher GPx activity, potentially altering their optimal intake. Similarly, variations in GPX1 (rs1050450) and TXNRD1 are associated with altered antioxidant capacity and diabetes risk in observational studies. These genetic factors partly explain why some populations show protective effects while others exhibit harm from the same selenium exposure.

The primary dietary sources of selenium in a Western diet are Brazil nuts (one nut can exceed the daily RDA), seafood (tuna, sardines, shrimp), organ meats, muscle meats, poultry, eggs, and grains grown in selenium-rich soils. The selenium content of plant foods depends entirely on soil concentration, making geographic location a critical determinant of population selenium status.

Global Selenium Status Variations

Regions such as the central United States, Canada, Japan, and Venezuela have high selenium soils, while parts of China, Europe (especially Eastern Europe and Scandinavia), New Zealand, and sub-Saharan Africa are characterized by low selenium soils. Consequently, dietary selenium intakes range from under 10 μg/day in some Chinese provinces to over 200 μg/day in parts of Venezuela. These disparities have profound implications for interpreting global research: a study reporting harm from selenium supplementation in the United States may not apply to a selenium-deficient population in China.

Selenium Supplementation: To Take or Not to Take

Given the risk of oversupplementation, most medical organizations recommend against routine selenium supplements for diabetes prevention. The American Diabetes Association does not endorse selenium for glycemic control, and the Endocrine Society’s guidelines on nutritional interventions stress the importance of obtaining nutrients from food rather than pills.Selenium supplementation should be reserved for individuals with documented deficiency due to conditions such as malabsorption, parenteral nutrition, or residence in low-selenium regions with muscle weakness and cardiomyopathy. In such cases, modest doses (50–100 μg/day) under medical supervision are appropriate.

Special Populations: Prediabetes, Gestational Diabetes, and T1DM

Prediabetes and Metabolic Syndrome

Research on selenium and prediabetes is sparse but suggestive. A cross-sectional study of Chinese adults with prediabetes found that those with serum selenium in the second quartile (68–84 μg/L) had lower fasting glucose than those in the lowest or highest quartiles, consistent with a U-shaped relationship. In the Finnish Diabetes Prevention Study, baseline selenium intake was not associated with progression to diabetes, but higher intake was linked to greater weight gain over four years—another risk factor for diabetes.

Gestational Diabetes Mellitus (GDM)

Pregnancy demands increased selenium for fetal development and placental antioxidant defense. Some studies report lower selenium levels in women with GDM compared with healthy pregnant controls, while others show no difference or even higher levels. A meta-analysis of eight case-control studies indicated that selenium supplementation (200 μg/day) during pregnancy improved glycemic parameters and reduced markers of oxidative stress, but it did not significantly reduce GDM incidence. Larger randomized controlled trials are needed to clarify benefits and risks for this population.

Type 1 Diabetes

Type 1 diabetes (T1DM) is an autoimmune condition distinct from type 2. Selenium’s role here is primarily through its antioxidant effects in reducing oxidative stress from hyperglycemia. Patients with T1DM often have lower selenium levels due to urinary losses and altered metabolism. Some small intervention studies suggest that selenium supplementation (50–100 μg/day) may reduce HbA1c and improve lipid profiles in T1DM, but these findings are preliminary. Caution is warranted because concurrent autoimmune thyroiditis (common in T1DM) could be exacerbated by excessive selenium.

Clinical Implications and Practical Guidance

For clinicians and nutrition professionals, the key takeaway is that selenium’s relationship with diabetes risk is highly context-dependent. Factors such as baseline selenium status, genetic background, dietary patterns, and comorbidities must be considered before making recommendations.

  • Do not recommend selenium supplements for diabetes prevention in populations with adequate selenium intake (most of North America, Japan). Focus instead on a balanced diet rich in whole grains, lean proteins, and vegetables.
  • Screen for selenium deficiency in individuals at risk: those with malabsorptive disorders (Crohn’s disease, celiac disease), on total parenteral nutrition (TPN), living in low-selenium regions, or exhibiting unexplained muscle weakness or cardiomyopathy. Measure serum selenium or SELENOP.
  • For deficient patients, start with dietary adjustments (e.g., two Brazil nuts per week, tuna twice weekly) before considering a low-dose supplement (50–100 μg/day). Monitor selenium levels to avoid overshooting.
  • Be aware of co-supplementation: selenium often appears in multivitamin formulations at levels of 50–100 μg. Many people consume multiple sources simultaneously, pushing them toward the upper safe range. Advise patients to check total intake from all supplements.
  • Educate on Brazil nut dosage: one Brazil nut contains about 70–90 μg of selenium, so consuming more than three nuts per day can easily exceed the Tolerable Upper Intake Level.

Future Directions in Research

The selenium–diabetes nexus remains an active area of investigation. Upcoming priorities include large-scale randomized controlled trials stratified by baseline selenium status, genetic subtyping, and precision supplementation protocols. Additionally, emerging evidence suggests that selenium may affect not only type 2 diabetes but also diabetic complications such as nephropathy and retinopathy through modulation of inflammatory cytokines and fibrosis pathways. Long-term studies with hard endpoints (diabetes incidence, cardiovascular events) are needed to replace surrogate markers like HbA1c and fasting glucose.

Another promising avenue is the interplay between selenium and the gut microbiome. Recent rodent studies show that selenium supplementation alters the composition of gut microbiota, increasing short-chain fatty acid–producing bacteria that may improve insulin sensitivity. Whether this translates to humans remains to be determined.

Conclusion: Nuance, Not Dichotomy

The relationship between selenium and diabetes risk is neither straightforward nor universally predictable. Selenium is essential, and both deficiency and excess can perturb glucose metabolism—but the “optimal” level varies across populations and individuals. The available evidence does not support a one-size-fits-all recommendation for selenium supplementation to reduce diabetes risk. Instead, maintaining a moderate, food-based selenium intake appears most prudent. Healthcare professionals should assess individual selenium status, consider regional soil differences, and counsel patients accordingly. As research progresses, personalized nutrition strategies will likely emerge, but for now, the ancient wisdom of “nothing in excess” holds particularly true for selenium.

External References

  • Rayman, M.P. “The argument for increasing selenium intake.” British Journal of Nutrition (2008). View article
  • Stranges, S. et al. “Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial.” JAMA (1996). (Also SELECT trial) View on JAMA Network
  • National Institutes of Health, Office of Dietary Supplements. “Selenium – Health Professional Fact Sheet.” View at NIH ODS
  • Steinbrenner, H. et al. “Selenium and type 2 diabetes: a critical review of the epidemiological evidence.” Nutrients (2017). Open access from PMC
  • World Health Organization. “Selenium in human health and disease.” WHO eBook (2021). View WHO page